Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

Cantech Letter Announces Finalists for 2014 Cantech Letter Awards

Marketwired December 22, 2014

ProMetic Enters Into Strategic Alliance with GENERIUM Pharmaceuticals

Marketwired December 22, 2014

ProMetic Announces the Exercise of the Over-Allotment Option Under its Bought Deal Offering of Common Shares

Marketwired December 12, 2014

ProMetic Announces Closing of Bought Deal Offering of Common Shares

Marketwired December 9, 2014

ProMetic's PBI-4050 to Target Patients With the Metabolic Syndrome and Associated Type 2 Diabetes

Marketwired December 4, 2014

ProMetic Announces $25.1 Million Bought Deal Offering to Fund Strategic Growth Initiatives

Canada NewsWire November 18, 2014

ProMetic Reports its Third Quarter 2014 Highlights and Financial Results

Marketwired November 13, 2014

Vanderbilt University Study Demonstrates ProMetic's PBI-4050 Ability to Protect Against Diabetic Nephropathy in Type II Diabetes

Marketwired November 13, 2014

ProMetic's PBI-4050 Cleared to Commence Clinical Trials in Patients with Diabetic Kidney Disease

Marketwired November 11, 2014

ProMetic to Report its Third Quarter 2014 Financial Results and Hold Conference Call / Webcast

Marketwired November 7, 2014

ProMetic's Plasminogen IND and Clinical Program Cleared by FDA

Marketwired October 28, 2014

ProMetic to Hold a Plasminogen Update Conference Call/Webcast

Marketwired October 27, 2014

ProMetic's PBI-4050 to Target Idiopathic Pulmonary Fibrosis ("IPF") as One of Its Orphan Indications

Marketwired October 15, 2014

ProMetic to Be Added to S&P/TSX SmallCap Index

Marketwired September 16, 2014

ProMetic Reports Successful PBI-4050 Pre-IND Meeting with the FDA

Marketwired September 3, 2014

ProMetic Reports its Second Quarter 2014 Highlights and Financial Results

Marketwired August 14, 2014

ProMetic Announces Senior Management Promotion and Board of Directors Nomination

Marketwired August 12, 2014

ProMetic to Report its Second Quarter 2014 Financial Results and Hold Conference Call / Webcast

Marketwired August 11, 2014

ProMetic Secures $20 Million Follow-on Investment from Thomvest Seed Capital Inc.

Marketwired August 1, 2014

ProMetic Enters Into New Product Program With an Existing Multinational Client

Marketwired July 24, 2014